Nirogacestat belongs to the first generation of targeted therapy drugs

Although nirogacestat (nirogacestat) is often classified as a targeted drug category, it does not strictly belong to the traditional pathway drugs such as EGFR or ALK inhibitors classified "by generation". Instead, it belongs to a type of Gamma Secretase Inhibitor with an innovative mechanism, focusing on the targeted intervention of the Notch signaling pathway. As the only γ-secretase inhibitor drug currently known to be approved for Desmoid tumors, Nirogacestat can be considered to represent a new generation of mechanism-targeted drugs, which is different from previous first- and second-generation targeted drugs based on kinase structure design.

The core mechanism is to block the cleavage process of Notch receptor mediated by γ-secretase, thereby inhibiting the abnormal activation of the Notch pathway. Notch signaling has been proven to have the potential to drive tumor growth in Desmoid tumors, some solid tumors and even some leukemias, and γ-secretase, as the key enzyme for its activation, is regarded as the "functional switch" of this pathway. Nirogastat's precise site of action and strong broad-spectrum inhibition enable it to clinically demonstrate a sustained remission effect that is superior to traditional chemotherapy.

Due to the uniqueness of its mechanism, nirogalastat is not suitable for all types of cancer, but is precisely focused on tumor types that are highly dependent on Notch dysregulation, such as Desmoid tumors. Compared with traditional targeted drugs, its design concept is more innovative. It does not rely on the tyrosine kinase structure but directly interferes with the receptor protein cleavage and activation process. It represents a new direction for targeted therapy to intervene from "extracellular receptors" to "intracellular signaling modules".

From a research and development perspective,Nirogacestat is also expanding into the field of combination therapy with multiple solid tumors and immunity, demonstrating the scalability of its mechanism platform. Therefore, it can be said that Nirogacestat has opened a new chapter in γ-secretase-targeted drugs, marking the evolution of precision therapeutic drugs from classical pathway inhibition to deep signal regulation, and is truly one of the representatives of a new generation of innovative targeted drugs.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html